Pharmacia submits valdecoxib NDA

PHA submitted an NDA for its valdecoxib oral second generation COX-2 antagonist to treat acute pain, dysmenorrhea, osteoarthritis, and rheumatoid arthritis. The compound would be co-marketed with Pfizer (PFE). The company previously submitted an NDA for its injectable COX-2 inhibitor, parecoxib, which is a prodrug of valdecoxib (see BioCentury, Nov. 20, 2000). ...